BioCentury | Jun 2, 1997
Company News

PPD management update

...of research and CSO of PPDI's newly formed research subsidiary; formerly president and CEO of Ingenex Inc....
BioCentury | Jun 2, 1997
Company News

Ingenex, PPD, Sarco Inc. deal

...transaction involving 263,158 newly issued PPDI shares. PPDI, a contract research organization, also will acquire Ingenex's...
...subsidiary. Ingenex is a majority-owned subsidiary of Titan Pharmaceuticals Inc. (TTNP, South San Francisco, Calif.). Ingenex Inc....
BioCentury | Jun 2, 1997
Strategy

Expanding the concept of contract research

...263,158 newly issued shares of PPDI worth about $5.1 million. PPDI also will acquire from Ingenex Inc....
...GSX System functional genomics technology, including associated facilities and personnel, for $8.7 million in cash. Ingenex...
...Calif.). Both platforms will be incorporated into a new, unnamed PPDI subsidiary run by former Ingenex...
BioCentury | Nov 4, 1996
Finance

The money's in the bank

...the antiviral company, which is heavily laden with former Wellcome managers and researchers. PLUG PULLED: Ingenex Inc....
...the shares at $8.50-$9.50. TTNP was to purchase 222,222 shares to increase its ownership in Ingenex...
BioCentury | Jul 22, 1996
Finance

Billion-dollar biotech club

...million had the deal priced at $11.50. KDUS closed the week at $7.375. MARKET HOPEFULS: Ingenex Inc....
...price would give the gene therapy company (Menlo Park, Calif.) a $27 million market cap. Ingenex's...
...an option to purchase 222,222 shares in the offering, which would increase its ownership in Ingenex...
BioCentury | Jun 10, 1996
Company News

Titan other research news

...TTNP's Ingenex Inc. subsidiary received a $750,000 Phase II SBIR grant from the National Institutes of Allergy...
...discover and characterize gene fragments that appear capable of interfering with the replication of HIV. Ingenex...
BioCentury | Feb 27, 1995
Company News

Ingenex other research news

...genes that may be involved in the disease. GSEs are DNA, RNA or peptide fragments. Ingenex...
...improve the methods researchers use to identify regulatory elements capable of suppressing any biologic process. Ingenex Inc....
BioCentury | Feb 6, 1995
Clinical News

Multidrug resistance gene therapy with MDR-1 gene inserted into patients' stem cells isolated from blood: Ingenex Inc., one of Titan's operating companies, has

...drugs out of cells Indication: Advanced breast cancer treated with paclitaxel ( taxol ) Status: Ingenex Inc....
BioCentury | Oct 17, 1994
Company News

Ingenex other research news

...defects in tumor suppressor function Phase I testing should start in 1995, the company said Ingenex Inc....
BioCentury | Sep 12, 1994
Clinical News

MDR-1 gene: Began pilot trial

Ingenex Inc. , Menlo Park, Calif. Product: MDR-1 gene delivered ex vivo to blood precursor cells by a retroviral vector Indication: Protection of marrow and blood in chemotherapy Status: Began pilot trial in 10 patients with...
Items per page:
1 - 10 of 12
BioCentury | Jun 2, 1997
Company News

PPD management update

...of research and CSO of PPDI's newly formed research subsidiary; formerly president and CEO of Ingenex Inc....
BioCentury | Jun 2, 1997
Company News

Ingenex, PPD, Sarco Inc. deal

...transaction involving 263,158 newly issued PPDI shares. PPDI, a contract research organization, also will acquire Ingenex's...
...subsidiary. Ingenex is a majority-owned subsidiary of Titan Pharmaceuticals Inc. (TTNP, South San Francisco, Calif.). Ingenex Inc....
BioCentury | Jun 2, 1997
Strategy

Expanding the concept of contract research

...263,158 newly issued shares of PPDI worth about $5.1 million. PPDI also will acquire from Ingenex Inc....
...GSX System functional genomics technology, including associated facilities and personnel, for $8.7 million in cash. Ingenex...
...Calif.). Both platforms will be incorporated into a new, unnamed PPDI subsidiary run by former Ingenex...
BioCentury | Nov 4, 1996
Finance

The money's in the bank

...the antiviral company, which is heavily laden with former Wellcome managers and researchers. PLUG PULLED: Ingenex Inc....
...the shares at $8.50-$9.50. TTNP was to purchase 222,222 shares to increase its ownership in Ingenex...
BioCentury | Jul 22, 1996
Finance

Billion-dollar biotech club

...million had the deal priced at $11.50. KDUS closed the week at $7.375. MARKET HOPEFULS: Ingenex Inc....
...price would give the gene therapy company (Menlo Park, Calif.) a $27 million market cap. Ingenex's...
...an option to purchase 222,222 shares in the offering, which would increase its ownership in Ingenex...
BioCentury | Jun 10, 1996
Company News

Titan other research news

...TTNP's Ingenex Inc. subsidiary received a $750,000 Phase II SBIR grant from the National Institutes of Allergy...
...discover and characterize gene fragments that appear capable of interfering with the replication of HIV. Ingenex...
BioCentury | Feb 27, 1995
Company News

Ingenex other research news

...genes that may be involved in the disease. GSEs are DNA, RNA or peptide fragments. Ingenex...
...improve the methods researchers use to identify regulatory elements capable of suppressing any biologic process. Ingenex Inc....
BioCentury | Feb 6, 1995
Clinical News

Multidrug resistance gene therapy with MDR-1 gene inserted into patients' stem cells isolated from blood: Ingenex Inc., one of Titan's operating companies, has

...drugs out of cells Indication: Advanced breast cancer treated with paclitaxel ( taxol ) Status: Ingenex Inc....
BioCentury | Oct 17, 1994
Company News

Ingenex other research news

...defects in tumor suppressor function Phase I testing should start in 1995, the company said Ingenex Inc....
BioCentury | Sep 12, 1994
Clinical News

MDR-1 gene: Began pilot trial

Ingenex Inc. , Menlo Park, Calif. Product: MDR-1 gene delivered ex vivo to blood precursor cells by a retroviral vector Indication: Protection of marrow and blood in chemotherapy Status: Began pilot trial in 10 patients with...
Items per page:
1 - 10 of 12